Seriously Health Review: What Its GLP-1 Documentation Establishes—and What It Leaves Open

01The first evidence gap is the medicine itself

Seriously Health describes injections available through office walk-ins or shipment to a patient’s home for self-administration. That establishes an advertised delivery model, not a fully identified drug offering. The consulted pages do not specify active ingredients, brands, concentrations, package presentations or whether the GLP-1 preparations are compounded. Without those details, a reader cannot reliably match the advertised treatment to a particular approved product or published trial.

The homepage says its pharmaceuticals come from U.S.-based, FDA-registered and cGMP-certified pharmacies and manufacturers. Those are provider claims; the consulted documentation does not name the organizations or independently establish their credentials. FDA approval concerns a specific drug product, not approval of Seriously Health as a clinic. Nor does a general sourcing statement establish the regulatory status, composition or quality of an unidentified prescription.

The useful next step is to request the proposed product’s exact name, formulation, presentation and dispensing pharmacy before ordering. Our guide to approved medicines and compounded preparations explains why these are separate evidence questions. FDA states that compounded preparations are not FDA approved and recommends them when an individual’s medical needs cannot be met by an approved drug, with a prescription and a state-licensed pharmacy. Nonapproval alone does not demonstrate clinical inequivalence.

02Clinical research cannot fill in missing product details

The public documentation reviewed here does not provide independently verified clinical outcomes for Seriously Health’s own patients. Its statements about helping patients and providing personalized care describe the practice’s positioning, not a controlled assessment of results. Even well-established research on a named medicine cannot supply missing information about this clinic’s product, patient selection or follow-up outcomes. The distinction is explained further in why a clinical trial is not a company performance report.

For example, STEP 1 studied 1,961 adults with obesity or overweight plus a weight-related condition, without diabetes, for 68 weeks. Both groups received lifestyle intervention. Mean weight change was −14.9% with studied subcutaneous semaglutide 2.4 mg weekly versus −2.4% with placebo. That dose identifies the research arm, not patient instructions. Gastrointestinal events led to discontinuation in 4.5% versus 0.8%; Novo Nordisk funded the trial. These are not Seriously Health outcomes or predictions for an individual.

The clinic’s broader language also needs context. It says its most common patients have BMI above 25 and have plateaued after lifestyle changes; that is not an automatic prescribing criterion. NIDDK describes general adult pharmacotherapy thresholds of BMI 30 or higher, or 27 or higher with weight-related health problems. The practice also says certain prescription medicines may be inappropriate for patients who are pregnant, breastfeeding or trying to conceive, or who have end-stage kidney or liver disease. These are medication-specific screening considerations, not a determination that every listed condition excludes every treatment. Medication-specific criteria and clinical assessment still matter. Seriously Health itself states that payment does not guarantee a prescription or its dispensing.

03What the Virginia practice actually documents

The terms identify Seriously Health, LLC as a medical practice in Virginia Beach. The footer separately describes a patient-management platform working with employed physicians and practitioners. The homepage says the practice opened in 2010 and offers oral, injectable and supplemental weight-loss medications. These descriptions establish a broader weight-management business rather than a GLP-1-only service, although the history and scale of its patient experience remain provider statements rather than independently verified findings.

The published clinical roster includes Patrick Fortes, MD, described as a board-certified physician, and Veronica Malone, Nisha Rathnayake and Gaida Celiz, each listed as a family nurse practitioner. Those are the credentials presented by the practice; this review did not verify licenses or certification. The terms restrict all services to Virginia, including telehealth for Virginia residents. A remote appointment option therefore should not be read as nationwide availability.

For local access, the clinic lists 130 Business Park Dr., Virginia Beach, VA 23462, near Town Center, with free parking and walk-in availability. Published hours are Monday through Friday, 9 a.m.–5:30 p.m., and Saturday, 9 a.m.–2 p.m., with Sunday closure and a noon–1 p.m. lunch closure. Patients can contact support@seriouslyhealth.com or call 757-219-2020. The site says texts, emails and calls are answered in its office, without call centers or AI chatbots; it does not establish a guaranteed response time.

04The consultation process is clearer than the final treatment bill

Online booking directs patients to Vagaro, which Seriously Health describes as its HIPAA-compliant electronic health record platform. Patients select an appointment date and professional, enter contact information and complete a medical-history form. At the initial appointment, the provider says it reviews goals and medical history and may order necessary tests or medicines. The resulting plan may include lifestyle recommendations and prescription treatment when appropriate; the booking process itself does not establish clinical acceptance.

The homepage lists an initial visit at $150 and monthly follow-up at $100. The GLP-1 page separately advertises treatment starting at $299 for a one-month supply, with changes possible according to dosage, individual needs or a switch in GLP-1 type. It also offers weekly office injections billed per visit, without publishing that option’s per-visit price in the consulted material. These are documented prices, but they do not resolve the combined cost.

Before paying, request an itemization identifying consultation charges, the exact medicine, administration, supplies, shipping and any testing. The pages do not clarify whether the $299 medication offer includes the $150 initial or $100 follow-up visit. Nor do they establish a fixed price as treatment changes. The $25 in-office blood-draw charge is specifically a drawing fee, not a documented all-inclusive laboratory price; processing and electrocardiogram costs remain unresolved.

05The membership advertisement needs its own explanation

The homepage advertises “2026 GLP-1 3 Month Memberships” starting at $89/month. That is materially different from the one-month medication offer starting at $299, but the documentation does not establish that they purchase equivalent services or supplies. The membership advertisement does not identify a product, quantity, eligibility conditions, total amount due, upfront collection requirement or renewal arrangement. Its three-month label alone establishes neither medication quantity nor a minimum contractual commitment.

The terms add another unresolved distinction: they state that Seriously Health does not use subscriptions or automatic payments and that patients are not locked into a recurring plan. The GLP-1 page also states that no membership is required. These statements may describe a different arrangement from the advertised three-month membership, but the consulted pages do not explain the relationship. Readers should ask for the membership’s written inclusions, billing schedule and cancellation provisions rather than treating $89 as a replacement price for the documented $299 supply.

Seriously Health operates on a self-pay basis and does not accept insurance as payment. It lists major credit and debit cards, cash and CareCredit, with HSA/FSA accepted for appointments. The privacy policy allows documentation when a patient requests insurer reimbursement, without promising coverage. That is distinct from the clinic accepting insurance. The documentation also does not establish that HSA/FSA acceptance extends to every medication purchase or that financing has no additional conditions.

06Shipping promises leave responsibilities to clarify

Seriously Health advertises medication availability at a first clinic visit or through two-day shipping. This describes a promoted access option, not a guaranteed interval from booking to arrival. It does not establish how long evaluation, prescribing, pharmacy processing or dispatch will take. The consulted pages also do not identify the carrier, shipping fee, cold-chain method or replacement arrangements for lost or damaged packages. Those details matter before choosing home delivery over office administration.

For a first home shipment, the practice promises guidance in person or by phone to support self-administration. That is a useful documented service, though it does not identify who supplies the instruction or how later questions are handled outside office hours. Request instructions tied to the actual product and presentation, plus the dispensing pharmacy’s contact details. FDA reports measurement and administration errors involving compounded medication, some associated with hospitalization; a review should never be used to calculate a dose.

Temperature concerns require more than a general reassurance about shipping speed. FDA explicitly recommends not using an injectable GLP-1 drug that arrives warm or with insufficient refrigeration and contacting the provider or dispensing pharmacy. Our guide to reading delivery and cold-chain claims separates transit advertising from documented handling safeguards. Seriously Health’s terms also exclude emergency and urgent care, so its office support should not be mistaken for either service.

07Follow-up has substance, but testing rules are treatment-specific

The practice describes monthly follow-up in person or by telehealth to review progress, medication tolerance, laboratory needs and treatment adjustments. That is more informative than a simple promise of refills. It also says patients whose BMI falls below 25 are reassessed for possible maintenance treatment rather than automatically continued or discontinued. NIDDK describes treatment duration as dependent on response and side effects; the clinic’s public statements do not establish an individual’s maintenance plan or future cost.

The site states that patients taking only GLP-1 medicines do not require labs. That is the practice’s published policy, not a universal clinical conclusion. It accepts outside results up to six months old through email or the patient profile, and virtual patients can obtain ordered bloodwork at an external laboratory. The initial-consultation description still allows necessary testing. Ask which tests, if any, the treating clinician expects for the particular proposed plan and how results are reviewed.

Other medication pathways have different requirements. The practice requires an EKG and bloodwork no more than six months old before prescribing controlled substances and stimulants, naming phentermine, diethylpropion and phendimetrazine. Initiation requires an in-office visit; it describes virtual refills for six consecutive follow-ups. These restrictions should not be generalized to GLP-1 care. Our guide to clinical follow-up beyond renewals explains why monitoring responsibilities deserve attention separately from the payment schedule.

08Consent, privacy and cancellation deserve a close reading

Two consent statements need reconciliation. The FAQ says the practice sees patients ages 12 and older with pediatric obesity and requires written consent from both the patient and parent or legal guardian. It distinguishes medicines approved from age 12 from others that may be appropriate only at 16 or 18, and states that some pediatric treatments may be prescribed off-label without FDA approval for pediatric use. The advertised minimum age therefore does not establish eligibility for a particular medicine. Separately, the terms require someone consenting to services to be at least 18 and a Virginia resident. Families should ask which documents govern enrollment and who signs each agreement. The public language does not explain how these provisions operate together.

The homepage’s “100% private” direct-pay advertising also needs qualification. Its privacy policy permits information sharing to coordinate treatment with laboratories, pharmacies and specialists, alongside legally required disclosures. Avoiding an insurance payment transaction therefore is not a documented promise of zero information exchange. Patients may request medical records in an available or agreed format, with possible reasonable copying fees. Ask how booking information, clinical records and pharmacy communications are handled rather than relying on the marketing phrase alone.

Bookings require a 50% deposit applied to the visit, with the balance due at service. Cancellation or rescheduling is free with more than 24 hours’ notice; cancellation or nonattendance within 24 hours forfeits the deposit. Prescription medicines cannot be returned or refunded once ordered or delivered, even unopened. Patients may leave the program at any time, but past visits are nonrefundable. After more than six months without care, the next appointment is scheduled as an initial consultation. The terms also include binding arbitration and a class-action waiver, and purport to limit liability to the lesser of amounts paid during the preceding six months or $100. These are published contract provisions; this review does not assess their legal enforceability.

Questions & answers

Sources & documentation

Public materials consulted October 19, 2026. Provider statements are attributed claims, not independently verified clinical outcomes. Terms can change; obtain a current written quote.

1. FDA concerns with unapproved GLP-1 drugs used for weight loss ↗
2. NIDDK: prescription medications for overweight and obesity ↗
3. Wilding et al. (2021): STEP 1 semaglutide trial ↗
4. Seriously Health — privacypolicy ↗
5. Seriously Health — glp1 ↗
6. Seriously Health — official website ↗
7. Seriously Health — termsandconditions ↗

Continue reading

• FDA-Approved Medicines and Compounded Preparations: Separate Evidence Questions
• A Clinical Trial Is Not a Telehealth Company Performance Report
• Reading GLP-1 Cold-Chain and Delivery Claims Carefully
• Follow-up Is a Clinical Question, Not Just a Renewal Notice
• What Public GLP-1 Provider Documents Can—and Cannot—Prove